What is it about?
Very elderly patients with non-squamous NSCLC show high rates of driver alterations in EGFR and ALK
Featured Image
Why is it important?
Testing for EGFR and ALK alterations should not be restricted to younger patients, as they often are not suitable for cytotoxic therapy and may benefit from targeted treatments.
Perspectives
Biology of NSCLC in very elderly may be different.
Professor Rudolf M. Huber
University of Munich and Thoracic Oncology Centre Munich
Read the Original
This page is a summary of: Frequency and clinical relevance of EGFR mutations and EML4–ALK translocations in octogenarians with non-small cell lung cancer, OncoTargets and Therapy, October 2017, Dove Medical Press,
DOI: 10.2147/ott.s140472.
You can read the full text:
Contributors
The following have contributed to this page
